Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F15%3A10293577" target="_blank" >RIV/00216208:11140/15:10293577 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/15:10293577

Výsledek na webu

<a href="http://dx.doi.org/10.4149/neo_2015_021" target="_blank" >http://dx.doi.org/10.4149/neo_2015_021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2015_021" target="_blank" >10.4149/neo_2015_021</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield

Popis výsledku v původním jazyce

Advances in understanding the pathogenesis of chronic myeloid leukemia (CML) and implementation of the therapy with tyrosine kinase inhibitors (TKI) could be considered as a prototype of successful fight against cancer. However, for an optimally responding patient it is recommended to follow the TKI therapy indefinitely. The question about the possibility of safe TKI treatment discontinuation in certain clinical situations was raised and is currently under close investigation worldwide. Currently, imatinib discontinuation trails have shown that about 60% of eligible patients experienced molecular recurrence within 6 months of treatment discontinuation, while the remaining 40% remained in defined deep molecular response throughout the duration of mostlytwo years follow-up. Interestingly, retreatment with the same TKI or another TKI was successful in the vast majority of patients demonstrating molecular recurrence of the disease. These findings support the concept of safe TKI treatment

Název v anglickém jazyce

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield

Popis výsledku anglicky

Advances in understanding the pathogenesis of chronic myeloid leukemia (CML) and implementation of the therapy with tyrosine kinase inhibitors (TKI) could be considered as a prototype of successful fight against cancer. However, for an optimally responding patient it is recommended to follow the TKI therapy indefinitely. The question about the possibility of safe TKI treatment discontinuation in certain clinical situations was raised and is currently under close investigation worldwide. Currently, imatinib discontinuation trails have shown that about 60% of eligible patients experienced molecular recurrence within 6 months of treatment discontinuation, while the remaining 40% remained in defined deep molecular response throughout the duration of mostlytwo years follow-up. Interestingly, retreatment with the same TKI or another TKI was successful in the vast majority of patients demonstrating molecular recurrence of the disease. These findings support the concept of safe TKI treatment

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14227" target="_blank" >NT14227: Stanovení prediktivních faktorů pro léčebný efekt chemoterapie u nemocných s karcinomem žaludku</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neoplasma

ISSN

0028-2685

e-ISSN

—

Svazek periodika

62

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

5

Strana od-do

167-171

Kód UT WoS článku

000362862400001

EID výsledku v databázi Scopus

2-s2.0-84943633434